§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇮🇩Indonesia	🇺🇸United States
Authority & dossier
Regulatory authority	BPOM	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +5	—
Lead pathway (timeline & fees) — New Drug Registration (NCE / new biologic / new indication) · New Drug Application — 505(b)(1)
Pathway name	New Drug Registration (NCE / new biologic / new indication)	New Drug Application — 505(b)(1)
Approval timeline	300–540 days	304–365 days
Application fee	IDR 5,000,000	USD 4,310,002
Annual renewal	IDR 0	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	NIE holders must designate an Apoteker Penanggung Jawab (Responsible Pharmacist) for the licensed premises, and a contact person for pharmacovigilance reporting to BPOM's Pharmacovigilance Centre.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Public Health Emergency / Emergency Use Authorisation (EUA), Accelerated Registration for Critical Need / SRA-approved Products	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per BPOM Regulation No. 23/2025 and ASEAN Variation Guideline into Major Variation (MaV — BPOM approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	NIE is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety, labelling and Halal status information.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	BPOM's Pharmacovigilance Centre (Pusat Farmakovigilans) coordinates national ADR reporting (Indonesia is a member of the WHO Programme for International Drug Monitoring, Uppsala). NIE holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–60 days	30–30 days
GCP standard	ICH E6(R2) GCP; BPOM Pedoman Cara Uji Klinik yang Baik (CUKB / Indonesian GCP)	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	InaHTAC — Indonesian Health Technology Assessment Committee	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

IndonesiaBPOM
United StatesFDA

English submissions

IndonesiaYes
United StatesYes

CTD accepted

IndonesiaYes
United StatesYes

eCTD accepted

IndonesiaNo
United StatesYes

Reliance pathway

IndonesiaAvailable
United StatesNone

Reference agencies

IndonesiaFDA (US), EMA, MHRA (UK), Health Canada +5
United States—

Lead pathway (timeline & fees) — New Drug Registration (NCE / new biologic / new indication) · New Drug Application — 505(b)(1)

Pathway name

IndonesiaNew Drug Registration (NCE / new biologic / new indication)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Indonesia300–540 days
United States304–365 days

Application fee

IndonesiaIDR 5,000,000
United StatesUSD 4,310,002

Annual renewal

IndonesiaIDR 0
United StatesUSD 416,734

Local representative

IndonesiaRequired
United StatesNot required

Local manufacturing

IndonesiaNot required
United StatesNot required

GMP inspection

IndonesiaRequired
United StatesRequired

MAH & local presence

Local entity required

IndonesiaYes
United StatesNo

Local responsible person

IndonesiaYes
United StatesYes

RP role

IndonesiaNIE holders must designate an Apoteker Penanggung Jawab (Responsible Pharmacist) for the licensed premises, and a contact person for pharmacovigilance reporting to BPOM's Pharmacovigilance Centre.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Indonesia2 designations
United States6 designations

Examples

IndonesiaPublic Health Emergency / Emergency Use Authorisation (EUA), Accelerated Registration for Critical Need / SRA-approved Products
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

IndonesiaVariations classified per BPOM Regulation No. 23/2025 and ASEAN Variation Guideline into Major Variation (MaV — BPOM approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

IndonesiaNIE is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety, labelling and Halal status information.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

IndonesiaBPOM's Pharmacovigilance Centre (Pusat Farmakovigilans) coordinates national ADR reporting (Indonesia is a member of the WHO Programme for International Drug Monitoring, Uppsala). NIE holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

IndonesiaAvailable
United StatesAvailable

Compassionate Use

IndonesiaAvailable
United StatesAvailable

Emergency Import

IndonesiaAvailable
United StatesAvailable

Parallel Import

IndonesiaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

IndonesiaRequired
United StatesRequired

Ethics approval

IndonesiaYes
United StatesYes

CTA timeline

Indonesia30–60 days
United States30–30 days

GCP standard

IndonesiaICH E6(R2) GCP; BPOM Pedoman Cara Uji Klinik yang Baik (CUKB / Indonesian GCP)
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

IndonesiaRegulated
United StatesFree pricing

Reference pricing

IndonesiaYes
United StatesNo

HTA required

IndonesiaYes
United StatesNo

HTA body

IndonesiaInaHTAC — Indonesian Health Technology Assessment Committee
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding